NRIX

NURIX THERAPEUTICS INC

NRIX·67080M103·US·Common Stock·Healthcare - Biotechnology-13D/G

NRIX (NURIX THERAPEUTICS INC) is held by 113 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($212.8M), FMR LLC ($133.1M), MORGAN STANLEY ($115.5M). Net institutional sentiment: Mixed.

113
Holders
(7 Elite)
$1.5B
Total Value
51% (115)
Consensus
59 buying - 56 selling
13F: Insider & Congress: Updated regularly
NRIX

Smart Money Verdict

View all
Loading verdict
Held by 113 funds
7 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Aug 5, 2026 · Activists Aug 14, 2026 · Congress none

ActivistRURubric Capital Management LP7.0%Aug 14, 2026
ActivistT. Rowe Price Associates, Inc.T. Rowe Price Associates, Inc.5.3%Aug 14, 2026
ActivistVPVestal Point Capital, LP7.8%Aug 14, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
8.8M(-1.7%)$212.8M0.0%+44.20%
0
Decreased
5.5M(-1.0%)$133.1M0.0%+49.08%
0
Decreased
4.8M(-3.4%)$115.5M0.0%+45.92%
0
Decreased
4.7M(-9.0%)$113.5M0.0%+78.74%
0
Unchanged
4.7M$113M0.6%+12.02%
0
Increased
4.5M(+1.6%)$109.1M0.0%+67.58%
30
Increased
2.5M(+0.7%)$61.6M0.0%+35.81%
30
Decreased
2.4M(-13.8%)$57M0.1%+55.68%
0
Increased
1.8M(+4.2%)$43.5M0.3%+111.07%
36
Increased
1.8M(+100.1%)$43.4M0.0%+33.30%
47
Increased
1.5M(+34.5%)$36M0.0%+48.56%
37
Increased
1.5M(+9.9%)$35.8M0.0%+47.20%
32
Increased
1.4M(+83.3%)$34.7M0.0%+51.10%
45
Increased
1.1M(+15.0%)$25.8M0.1%+34.56%
33
Decreased
983,462(-16.7%)$23.9M0.0%+64.00%
0
Decreased
983,462(-16.7%)$23.8M0.3%+64.05%
0
Decreased
917,117(-6.1%)$22.2M0.0%+83.46%
0
Increased
876,070(+2.5%)$21.3M0.0%+25.58%
29
Increased
842,089(+5.0%)$20.4M0.0%+72.48%
30
Decreased
833,296(-9.8%)$20.2M0.0%+68.83%
0

Showing 1-20 of 124

1 / 7
NRIXNRIXNURIX THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used